Analyst Ratings for [TVTX] Travere Therapeutics Inc

1/10/25	Initiated	Overweight	X
TVTX Travere Therapeutics Cantor Fitzgerald
10/21/24	Upgrades	Eq Weight Overweight	X
TVTX Travere Therapeutics Wells Fargo
$9 $27
10/16/24	Initiated	Sector Outperform	X
TVTX Travere Therapeutics Scotiabank
9/9/24	Upgrades	Neutral Buy	X
TVTX Travere Therapeutics Guggenheim
$25
3/27/24	Downgrades	Buy Neutral	X
TVTX Travere Therapeutics Guggenheim
12/5/23	Upgrades	Neutral Buy	X
TVTX Travere Therapeutics Citigroup
$7 $10
11/20/23	Initiated	Neutral	X
TVTX Travere Therapeutics Citigroup
$7
9/22/23	Downgrades	Overweight Eq Weight	X
TVTX Travere Therapeutics Wells Fargo
$24 $8
9/21/23	Downgrades	Outperform Mkt Perform	X
TVTX Travere Therapeutics William Blair
9/6/23	Resumed	Outperform	X
TVTX Travere Therapeutics Evercore ISI
$30
7/21/23	Initiated	Overweight	X
TVTX Travere Therapeutics JP Morgan
$26
6/7/23	Resumed	Neutral	X
TVTX Travere Therapeutics Piper Sandler
$22
5/22/23	Initiated	Outperform	X
TVTX Travere Therapeutics TD Cowen
$30
5/5/23	Upgrades	Sell Neutral	X
TVTX Travere Therapeutics Bryan Garnier
3/1/23	Initiated	Buy	X
TVTX Travere Therapeutics Guggenheim
$37
2/21/23	Upgrades	Neutral Outperform	X
TVTX Travere Therapeutics Wedbush
$30
12/14/22	Initiated	Hold	X
TVTX Travere Therapeutics Stifel
$22
12/5/22	Initiated	Overweight	X
TVTX Travere Therapeutics Wells Fargo
$28
9/21/22	Initiated	Sell	X
TVTX Travere Therapeutics Bryan Garnier
$17
7/14/22	Resumed	Buy	X
TVTX Travere Therapeutics Canaccord Genuity
$49 $42
3/31/22	Initiated	Overweight	X
TVTX Travere Therapeutics Piper Sandler
$42
5/26/21	Downgrades	Outperform Neutral	X
TVTX Travere Therapeutics Wedbush
$19
2/16/21	Resumed	Overweight	X
TVTX Travere Therapeutics Barclays
$40

TVTX Travere Therapeutics Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.